Aldevron

Innovation doesn't happen in isolation.

That's why we're proud to support BioForward Wisconsin and the 2026 Wisconsin Biohealth Summit as a Gold Medallion Sponsor. BioForward plays an important role in connecting and advancing Wisconsin's biohealth ecosystem, bringing together researchers, manufacturers, entrepreneurs, investors, and healthcare leaders to help drive innovation forward.

This year's Summit, themed"From Molecule to Medicine: Delivering Successful Patient Outcomes," highlights the collaboration required to turn scientific discoveries into real-world impact.

We're looking forward to joining conversations around the science, technologies, partnerships, and investment helping shape the future of biohealth in Wisconsin and beyond.

Register here: https://ald.bio/4ihy5da

Behind every breakthrough are people working to make a difference.

On September 27, Team Aldevron participated in the Badger Challenge, joining a passionate community committed to advancing cancer research and supporting patients and families impacted by cancer.

We're proud of our associates who showed up as riders, runners, walkers, volunteers, fundraisers, and supporters, all contributing to a cause that reflects the impact science can have on people's lives.

Thank you to everyone who participated and helped support this important mission. We're honored to be part of a community working toward a future with more hope and more possibilities for patients.

💙 Take a look at some highlights from the event.

October 10 is World Mental Health Day.

Mental health is an essential part of our overall well-being, influencing how we learn, work, build relationships, and navigate everyday life. Around the world, this day serves as an opportunity to raise awareness, reduce stigma, and encourage meaningful conversations about mental health.

This year, we recognize the importance of listening, understanding, and supporting one another. Every conversation has the potential to make a difference.

A growing portfolio of Aldevron research products is now available through our Online Store.
• DNA
• RNA
• Proteins
• Nanoplasmid™ vectors
• Viral vector plasmids

Browse products, view pricing and quotations, and order on your timeline.
The same quality.
The same scientific expertise.
A faster path to the materials you need.

Check out the store now: https://ald.bio/4zgl21k

What happens when research-stage decisions don't align with manufacturing realities?

In this on-demand webinar, Aldevron's experts discuss how choices made early in mRNA development can impact scalability, comparability, tech transfer, and regulatory readiness later on.

Learn strategies for:

• Selecting phase-appropriate approaches for templates, IVT, and analytics
• Reducing risks associated with variability and dsRNA formation
• Supporting smoother transitions from research-grade material to cGMP manufacturing

Watch on demand: https://ald.bio/3WcXo7z

As cell therapy programs advance toward Phase III and commercialization, CDMO requirements change dramatically.

Questions that may not seem urgent today can become costly constraints later:

✅ Manufacturing scale
✅ Regulatory readiness
✅ Supply continuity
✅ Commercial experience

The challenge is not whether your current CDMO has worked so far. The challenge is whether it's prepared for what's next.

Our Switch UP Readiness Assessment helps teams evaluate potential gaps before critical milestones are at stake.

Download the checklist and assess your readiness with confidence: https://ald.bio/4AODRdL

Day 2 at Meeting on the Mesa is in the books.

It's been another great day of conversations with innovators, researchers, and industry leaders working to advance the future of cell and gene therapies. From partnering meetings to discussions around manufacturing, scalability, and commercialization, we're seeing firsthand the momentum driving this field forward.

If you're attending, there's still time to connect with the Aldevron team. Stop by Table F17 or visit us in the Canyon Room to continue the conversation.

Looking forward to another day of insights, collaboration, and new connections tomorrow.

The conversations at Meeting on the Mesa continue to reinforce an important shift across the cell and gene therapy industry.

The focus is no longer just on proving the science. Discussions are increasingly centered on manufacturing scalability, regulatory confidence, and the path to commercial success.

We're hearing thoughtful conversations around what it will take to move innovative therapies from promising concepts to broader patient impact, and it's encouraging to see continued optimism about the future of the field.

If you're attending Meeting on the Mesa, stop by the Aldevron table to connect with our team. We'd love to hear what's top of mind for you and your organization.

One of the most expensive words in advanced therapy development is "later."

We'll figure out quality later.

We'll think about scalability later.

We'll revisit documentation later.

We'll address sourcing later.

For gene-modified cell therapy programs, those "later" decisions often become the bottlenecks that are hardest to solve.

As programs move toward clinical ex*****on, success is no longer defined solely by scientific performance. Teams also need confidence in supply continuity, documentation, quality expectations, manufacturing readiness, and long-term scalability.

That doesn't mean every early-stage program needs a late-stage manufacturing strategy.

It means teams benefit from understanding whether today's material choices can support tomorrow's milestones.

The goal is not to eliminate complexity.

The goal is to avoid complexity that doesn't create value.

The earlier development teams evaluate those questions, the more options they typically have available when programs begin to accelerate.

When your program is preparing for what's next, it may be time to Switch-Up

Learn more: https://ald.bio/4yERQkl

CAMP-8677 Switch Up What worked well at earlier stages doesn’t always translate as programs advance. As you move toward later-stage development, increasing demands around capacity, quality systems, regulatory readiness, and delivery reliability can introduce new complexities and require a partner equipped to support ...